Real-World Gestational Diabetes Screening: Problems with the Oral Glucose Tolerance Test in Rural and Remote Australia
Abstract
:1. Introduction
2. Materials and Methods
- Fasting plasma glucose ≥ 5.1 mmol/L
- 1-h plasma glucose ≥ 10.0 mmol/L
- 2-h plasma glucose ≥ 8.5 mmol/L
- FLOXRT protocol: FLOX tube (5 mL BD Biosciences, Australia) stored at room temperature. Aliquots collected at 0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, and 4 h.
- FLOXICE protocol: FLOX tube (2 mL BD Biosciences, Australia) placed immediately in ice-slurry. Aliquots collected at 0.25 h, 0.5 h, 0.75 h, and 1 h.
- FC Mix protocol: FC Mix tube (3 mL) stored at room temperature. Aliquots collected at 0.25 h, 0.5 h, 0.75 h, 1 h, and 4 h.
- PST protocol: PST (3 mL BD Biosciences, Australia), centrifuged within 5 min of collection at 1300× g for 5 min, and stored at room temperature. Separated plasma fraction remained in the collection tube for the entire experiment.
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Appendix A
Pathology Laboratory | Location | Fasting Duration | Preferred Specimen | Storage/Transport |
---|---|---|---|---|
Abbott Pathology Laboratory | SA Statewide | 10–12 h (max 16 h) | fluoride-oxalate | No recommendation |
ACT Pathology | ACT Territory wide | 8–12 h | fluoride-oxalate | No recommendation |
Alfred Health | VIC Statewide | > 8 h (no max) | fluoride-oxalate | Transport at RT |
Austin Pathology | VIC Statewide | 8–12 h | fluoride-oxalate | No recommendation |
Australian Clinical Labs | WA Statewide | No recommendation | SST or fluoride-oxalate | No recommendation |
Australian Clinical Labs | SA Statewide | 10–14 h | fluoride-oxalate or capillary if difficult bleed | No recommendation |
Australian Clinical Labs | NSW Statewide, VIC Statewide & NT Territory wide | 12–14 h | fluoride-oxalate or capillary if difficult bleed | No recommendation |
Cabrini Health | VIC Metropolitan | 8–12 h | No recommendation | No recommendation |
Capital Pathology | NSW Statewide & ACT territory wide | No recommendation | fluoride-oxalate | No recommendation |
Clinipath | WA Statewide | 10–16 h | fluoride-oxalate | No recommendation |
Dorevitch Pathology | VIC Statewide | 8–10 h | fluoride-oxalate | No recommendation |
Douglass Hanly Moir Pathology | NSW Statewide | 8–12 h | fluoride-oxalate | RT |
Eastern Health Pathology | VIC Metropolitan | Overnight (max 16 h) | fluoride-oxalate | No recommendation |
Goulburn Valley Health | VIC Regional | 10–14 h | fluoride-oxalate | Standard transport recommendation, ASAP 2–24 °C |
Hobart Pathology | TAS Metropolitan | 8–15 h | fluoride-oxalate | No recommendation |
Launceston Pathology | TAS Metropolitan | 8–15 h | fluoride-oxalate | No recommendation |
Laverty Laboratory | NSW & ACT Statewide | 8–14 h | fluoride-oxalate | Do not centrifuge; Refrigerate |
Melbourne Pathology | VIC Statewide | 8–12 h | fluoride-oxalate | No recommendation |
Monash Pathology | VIC Metropolitan | 8–16 h | fluoride-oxalate | No recommendation |
NSW Health Pathology—North | NSW Statewide | 10 h (no min or max) | fluoride-oxalate | No recommendation for storage; transport 2–8 °C |
NSW Health Pathology—SEALS | NSW South East | 8–10 h | fluoride-oxalate/EDTA | Refrigerate |
NSW Health Pathology—SSWPS | NSW Metropolitan | From 10 pm (no specific duration) | Not specified | If delayed separate serum and refrigerate; transport at RT |
Pathology Queensland | QLD Statewide | Overnight (no specific duration) | fluoride-oxalate | No storage recommendation; transport cool |
Pathology South | TAS Metropolitan | 8–16 h | fluoride-oxalate/EDTA | No recommendation |
Pathwest | WA Statewide | 10–16 h | fluoride-oxalate | No recommendation |
QML Pathology | QLD Statewide | 8–16 h | SST or fluoride-oxalate | No recommendation |
Royal Children’s Hospital Laboratory Services | VIC Metropolitan | 10 h (no min or max) | fluoride-oxalate | No recommendation |
SA Pathology | SA Statewide | 10–16 h | fluoride-oxalate | No storage recommendation; transport < 25 °C |
Southern IML | NSW Statewide | 10–12 h | SST | No recommendation |
St Vincent’s Pathology | VIC Metropolitan | 10 h (no min or max) | fluoride-oxalate | No recommendation |
Sullivan Nicolaides Pathology | QLD Statewide | 8–16 h | SST | No recommendation |
Sydpath | NSW Metropolitan | From 10 pm (no specific duration) | fluoride-oxalate | No recommendation |
TML Pathology | TAS Metropolitan | 8–12 h | Not specified | No recommendation |
Western Diagnostic | WA Statewide & NT Territory wide | No recommendation | fluoride-oxalate | No recommendation |
Women’s and Children’s Pathology, The Royal Children’s Hospital | VIC Metropolitan | 10 h | fluoride-oxalate or SST if centrifuged < 3 h if fluoride-oxalate not collected | No recommendation |
OGTT Sample | Timed Aliquot Plasma Glucose (mmol/L) | |||
---|---|---|---|---|
15 min | 30 min | 45 min | 1 h | |
Fasting | 4.9 ± 0.49 ** | 4.9 ± 0.46 * | 4.9 ± 0.47 | 4.9 ± 0.45 |
1-h | 6.5 ± 1.75 * | 6.6 ± 1.85 ** | 6.5 ± 1.76 | 6.4 ± 1.75 |
2-h | 5.8 ± 1.24 | 5.8 ± 1.25 | 5.8 ± 1.26 | 5.8 ± 1.28 |
Beta Coefficients (95% CI) p-Value | ||||
---|---|---|---|---|
Plasma Glucose | Delay | Delay^2 | Constant | |
FLOXICE algorithm | ||||
Fasting PG | 0.999 | 0.108 | −0.004 | 0.125 |
(0.966–1.032) p < 0.001 | (0.093–0.122) p < 0.001 | (−0.004–(−)0.003) p < 0.001 | (−0.034–0.283) p = 0.122 | |
1-h PG | 0.981 | 0.107 | −0.004 | 0.279 |
(0.961–1.000) p < 0.001 | (0.074–0.139) p < 0.001 | (−0.005–(−)0.002) p < 0.001 | (0.140–0.419) p < 0.001 | |
2-h PG | 0.949 | 0.091 | −0.003 | 0.426 |
(0.919–0.979) p < 0.001 | (0.055–0.127) p < 0.001 | (−)0.002) p < 0.001 | (0.243–0.610) p < 0.001 | |
FC mix algorithm | ||||
Fasting PG | 0.986 | 0.106 | −0.004 | 0.386 |
(0.953–1.019) p < 0.001 | (0.091–0.121) p < 0.001 | (−0.004–(−)0.003) p < 0.001 | (0.227–0.545) p < 0.001 | |
1-h PG | 1.043 | 0.112 | −0.004 | 0.146 |
(1.015–1.071) p < 0.001 | (0.066–0.158) p < 0.001 | (−0.006–(−)0.002) p < 0.001 | (−0.055–0.347) p = 0.154 | |
2-h PG | 1.098 | 0.105 | −0.004 | −0.182 |
(1.075–1.120) p < 0.001 | (0.078–0.132) p < 0.001 | (−0.005–(−)0.003) p < 0.001 | (−0.321–(−)0.044) p = 0.01 |
OGTT Sample | OGTT by Standard Procedures | Standard OGTT Adjusted by Song et al. Algorithm | Standard OGTT Adjusted by FC Mix Algorithm | ||||||
---|---|---|---|---|---|---|---|---|---|
Median Delay to Analysis (h) | PG | Cumulative GDM Diagnosis | PG | PG Difference vs. Standard Protocol | Cumulative GDM Diagnosis | PG | PG Difference vs. Standard Protocol | Cumulative GDM Diagnosis | |
Fasting | 4.9 (3.6–6.2) | 4.33 ± 0.44 | 19 (5.2) | 4.82 ± 0.49 | 0.49 ± 0.06 | 93 (25.3) | 5.04 ± 0.43 | 0.71 ± 0.12 | 167 (45.4) |
1-h | 3.8 (2.5–5.1) | 7.03 ± 1.79 | 34 (9.2) | 7.60 ± 1.93 | 0.57 ± 0.15 | 109 (29.6) | 7.80 ± 1.85 | 0.78 ± 0.15 | 179 (48.6) |
2-h | 2.9 (1.5–4.2) | 5.99 ± 1.50 | 43 (11.7) | 6.35 ± 1.59 | 0.37 ± 0.09 | 118 (32.1) | 6.62 ± 1.62 | 0.64 ± 0.20 | 186 (50.5) |
References
- Karuranga, S.; Fernandes, J.; Huang, Y.; Malanda, B. IDF Diabetes Atlas, 8th ed.; International Diabetes Federation: Brussels, Belgium, 2017; pp. 26–65. [Google Scholar]
- Metzger, B.E.; Gabbe, S.G.; Persson, B.; Buchanan, T.A.; Catalano, P.A.; Damm, P.; Dyer, A.R.; Leiva, A.; Hod, M.; Kitzmiler, J.L.; et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010, 33, 676–682. [Google Scholar] [CrossRef] [PubMed]
- Metzger, B.E.; Lowe, L.P.; Dyer, A.R.; Trimble, E.R.; Chaovarindr, U.; Coustan, D.R.; Hadden, D.R.; McCance, D.R.; Hod, M.; McIntyre, H.D.; et al. Hyperglycemia and adverse pregnancy outcomes. N. Engl. J. Med. 2008, 358, 1991–2002. [Google Scholar] [CrossRef] [PubMed]
- Pettitt, D.J.; Knowler, W.C.; Baird, H.R.; Bennett, P.H. Gestational diabetes: Infant and maternal complications of pregnancy in relation to third-trimester glucose tolerance in the Pima Indians. Diabetes Care 1980, 3, 458–464. [Google Scholar] [CrossRef]
- Clausen, T.D.; Mathiesen, E.R.; Hansen, T.; Pedersen, O.; Jensen, D.M.; Lauenborg, J.; Damm, P. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: The role of intrauterine hyperglycemia. Diabetes Care 2008, 31, 340–346. [Google Scholar] [CrossRef]
- Jensen, D.M.; Damm, P.; Sorensen, B.; Molsted-Pedersen, L.; Westergaard, J.G.; Klebe, J.; Beck-Nielsen, H. Clinical impact of mild carbohydrate intolerance in pregnancy: A study of 2904 nondiabetic Danish women with risk factors for gestational diabetes mellitus. Am. J. Obstet. Gynecol. 2001, 185, 413–419. [Google Scholar] [CrossRef]
- Sacks, D.A.; Greenspoon, J.S.; Abu-Fadil, S.; Henry, H.M.; Wolde-Tsadik, G.; Yao, J.F. Toward universal criteria for gestational diabetes: The 75-gram glucose tolerance test in pregnancy. Am. J. Obstet. Gynecol. 1995, 172, 607–614. [Google Scholar] [CrossRef]
- Chan, A.Y.; Swaminathan, R.; Cockram, C.S. Effectiveness of sodium fluoride as a preservative of glucose in blood. Clin. Chem. 1989, 35, 315–317. [Google Scholar]
- Diabetes Mellitus: Report of A WHO Study Group [meeting held in Geneva from 11 to 16 February 1985]; World Health Organization: Geneva, Switzerland, 1985.
- Nesbitt, G.S.; Smye, M.; Sheridan, B.; Lappin, T.R.; Trimble, E.R. Integration of local and central laboratory functions in a worldwide multicentre study: Experience from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Clin. Trials 2006, 3, 397–407. [Google Scholar] [PubMed]
- Hapo Study Cooperative Research Group. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Int. J. Gynaecol. Obstet. 2002, 78, 69–77. [Google Scholar] [CrossRef]
- Sacks, D.B.; Arnold, M.; Bakris, G.L.; Bruns, D.E.; Horvath, A.R.; Kirkman, M.S.; Lernmark, A.; Metzger, B.E.; Nathan, D.M.; Clinical, B.; et al. National Academy of Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011, 34, 61–99. [Google Scholar] [CrossRef] [PubMed]
- Tolonen, H.; Koponen, P.; Arornaa, A.; Conti, S.; Graff-Iversen, S.; Gretvedt, L.; Kanieff, M.; Mindell, J.; Natunen, S.; Primatesta, P.; et al. Recommendations for the Health Examination Surveys in Europe for the Feasibility of A European Health Examination Survey (FEHES) Project, B21; National Public Health Institute: Helsinki, Finland, 2008; pp. 99–100.
- Kleinwechter, H.; Schafer-Graf, U.; Buhrer, C.; Hoesli, I.; Kainer, F.; Kautzky-Willer, A.; Pawlowski, B.; Schunck, K.; Somville, T.; Sorger, M. Gestational Diabetes Mellitus (GDM) Diagnosis, Therapy and Follow-Up Care Practice Guideline of the German Diabetes Association (DDG) and the German Association for Gynaecology and Obstetrics (DGGG). Exp. Clin. Endocrinol. Diabetes 2014, 122, 395–405. [Google Scholar] [CrossRef] [PubMed]
- Carta, M.; Mosca, A.; Lapolla, A.; Testa, R. Society Italiana patologia Clinica 2015 recommendations for oral glucose tolerance testing (OGTT). Biochim. Clin. 2015, 39, 135–140. [Google Scholar]
- Eriksson-Boija, E.; Nordin, G. Swedish National Quality Goals for Measurement of Glucose: Guidance for the Laboratory; Equalis: Uppsala, Sweden, 2015; pp. 1–10. [Google Scholar]
- Chan, H.; Lunt, H.; Thompson, H.; Heenan, H.F.; Frampton, C.M.; Florkowski, C.M. Plasma glucose measurement in diabetes: Impact and implications of variations in sample collection procedures with a focus on the first hour after sample collection. Clin. Chem. Lab. Med. 2014, 52, 1061–1068. [Google Scholar] [CrossRef] [PubMed]
- Daly, N.; Flynn, I.; Carroll, C.; Farren, M.; McKeating, A.; Turner, M.J. Impact of Implementing Preanalytical Laboratory Standards on the Diagnosis of Gestational Diabetes Mellitus: A Prospective Observational Study. Clin. Chem. 2016, 62, 387–391. [Google Scholar] [CrossRef] [PubMed]
- Stapleton, M.; Daly, N.; O’Kelly, R.; Turner, M.J. Time and temperature affect glycolysis in blood samples regardless of fluoride-based preservatives: A potential underestimation of diabetes. Ann. Clin. Biochem. 2017, 54, 671–676. [Google Scholar] [CrossRef]
- Song, D.; Lia, M.; Hurley, J.C. Recommended pre-analytical plasma glucose sampling methodology may distort gestational diabetes mellitus prevalence: Implications for diagnostic thresholds. Diabet. Med. 2019, 11, 11. [Google Scholar] [CrossRef]
- Kirke, A.B.; Atkinson, D.; Moore, S.; Sterry, K.; Singleton, S.; Roxburgh, C.; Parrish, K.; Porter, C.; Marley, J.V. Diabetes screening in pregnancy failing women in rural Western Australia: An audit of oral glucose tolerance test completion rates. Aust. J. Rural Health 2019. [Google Scholar] [CrossRef]
- Jennings, B.; Joyce, A.; Pierce, A. Western Australia’s Mothers and Babies, 2014: 32nd Annual Report of the Western Australian Midwives’ Notification System; Department of Health, Western Australia: East Perth, Australia, 2018.
- Coburn, H.J.; Carroll, J.J. Improved manual and automated colorimetric determination of serum glucose, with use of hexokinase and glucose-6-phosphate dehydrogenase. Clin. Chem. 1973, 19, 127–130. [Google Scholar]
- Harris, P.A.; Taylor, R.; Thielke, R.; Payne, J.; Gonzalez, N.; Conde, J.G. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inf. 2009, 42, 377–381. [Google Scholar] [CrossRef]
- Gambino, R. Sodium fluoride: An ineffective inhibitor of glycolysis. Ann. Clin. Biochem. 2013, 50, 3–5. [Google Scholar] [CrossRef]
- Daly, N.; Stapleton, M.; O’Kelly, R.; Kinsley, B.; Daly, S.; Turner, M.J. The role of preanalytical glycolysis in the diagnosis of gestational diabetes mellitus in obese women. Am. J. Obstet. Gynecol. 2015, 213, 84.e1–84.e5. [Google Scholar] [CrossRef] [PubMed]
- Shen, E.X.; Moses, R.G.; Oats, J.J.N.; Lowe, J.; McIntyre, H.D. Seasonality, temperature and pregnancy oral glucose tolerance test results in Australia. BMC Pregnancy Childbirth 2019, 19, 263. [Google Scholar] [CrossRef] [PubMed]
- Brandhorst, G.; Engelmayer, J.; Gotze, S.; Oellerich, M.; von Ahsen, N. Pre-analytical effects of different lithium heparin plasma separation tubes in the routine clinical chemistry laboratory. Clin. Chem. Lab. Med. 2011, 49, 1473–1477. [Google Scholar] [CrossRef] [PubMed]
- Carey, R.; Lunt, H.; Heenan, H.F.; Frampton, C.M.; Florkowski, C.M. Collection tubes containing citrate stabiliser over-estimate plasma glucose, when compared to other samples undergoing immediate plasma separation. Clin. Biochem. 2016, 49, 1406–1411. [Google Scholar] [CrossRef]
- Desoye, G.; Nolan, C.J. The fetal glucose steal: An underappreciated phenomenon in diabetic pregnancy. Diabetologia 2016, 59, 1089–1094. [Google Scholar] [CrossRef]
- Troisi, R.J.; Cowie, C.C.; Harris, M.I. Diurnal Variation in Fasting Plasma GlucoseImplications for Diagnosis of Diabetes in Patients Examined in the Afternoon. JAMA 2000, 284, 3157–3159. [Google Scholar] [CrossRef]
- Agarwal, M.M. Gestational diabetes mellitus: Screening with fasting plasma glucose. World J. Diabetes 2016, 7, 279–289. [Google Scholar] [CrossRef]
- van den Berg, S.A.; Thelen, M.H.; Salden, L.P.; van Thiel, S.W.; Boonen, K.J. It takes acid, rather than ice, to freeze glucose. Sci. Rep. 2015, 5, 8875. [Google Scholar] [CrossRef]
- Mikesh, L.M.; Bruns, D.E. Stabilization of glucose in blood specimens: Mechanism of delay in fluoride inhibition of glycolysis. Clin. Chem. 2008, 54, 930–932. [Google Scholar] [CrossRef]
- Agarwal, M.M.; Dhatt, G.S.; Othman, Y. Gestational diabetes mellitus prevalence: Effect of the laboratory analytical variation. Diabetes Res. Clin. Pract. 2015, 109, 493–499. [Google Scholar] [CrossRef]
- Badrick, T.; Stewart, P. Measurement Uncertainty. In A Joint Initiative of Australian Doctor and the Royal College of Pathologists of Australasia; Flecknoe-Brown, S., Ed.; Cirrus Media: Chatswood, Australia, 2015. [Google Scholar]
- White, G.H.; Farrance, I. Uncertainty of measurement in quantitative medical testing: A laboratory implementation guide by the AACB Uncertainty of Measurement Working Group. Clin. Biochem. Rev. 2004, 25, S1–S24. [Google Scholar] [PubMed]
Characteristic | Total Cohort n (%) | OGTT Complete n = 501 (85.1%) | OGTT not Done or Incomplete n = 88 (14.9%) | p-Value |
---|---|---|---|---|
Maternal characteristics | ||||
Age (years) | 589 (100%) | 28.8 ± 5.7 | 27.1 ± 5.0 | 0.008 |
Ethnicity | < 0.001 | |||
Non-Indigenous | 324 (55.0%) | 300 (92.6%) | 24 (7.4%) | |
Aboriginal and Torres Strait Islander | 229 (38.9%) | 169 (73.8%) | 60 (26.2%) | |
Other high-risk ethnicity † | 36 (6.1%) | 32 (88.9%) | 4 (11.1%) | |
BMI after 24 weeks (kg/m2) | 589 (100%) | 28.5 ± 6.1 | 28.5 ± 7.2 | 0.92 |
BMI category ‡ | 0.28 | |||
Normal or underweight (≤ 28.4) | 330 (56.0%) | 281 (85.2%) | 49 (14.8%) | |
Overweight (28.5–32.9) | 130 (22.1%) | 115 (88.5%) | 15 (11.5%) | |
Obese (≥ 33.0) | 129 (21.9%) | 105 (81.4%) | 24 (18.6%) | |
Parity (prior delivery ≥ 20 weeks) ≥ 1 at enrolment | 401 (68.1%) | 336 (83.8%) | 65 (16.2%) | 0.21 |
Family history of diabetes § | 181 (30.7%) | 146 (80.7%) | 35 (19.3%) | 0.046 |
Any antenatal smoking | 162 (27.5%) | 116 (71.6%) | 46 (28.4%) | < 0.001 |
Antenatal urinary tract infection | 30 (5.1%) | 26 (86.7%) | 4 (13.3%) | 0.80 |
Previous caesarean delivery ¶ | 70 (17.5%) | 62 (88.6%) | 8 (11.4%) | 0.23 |
Length of gestation at first antenatal presentation (weeks) | 589 (100%) | 9.8 ± 5.8 | 11.2 ± 7.1 | 0.057 |
Remoteness classification of health service | 0.220 | |||
MMM2 | 50 (8.5%) | 48 (96.0%) | 2 (4.0%) | |
MMM3 | 383 (65.0%) | 320 (83.6%) | 63 (16.4%) | |
MMM6 | 78 (13.2%) | 72 (92.3%) | 6 (7.7%) | |
MMM7 | 78 (13.2%) | 61 (78.2%) | 17 (21.8%) | |
Newborn characteristics | ||||
Gestational age at delivery (weeks) | 589 (100%) | 39.2 ± 1.5 | 38.8 ± 1.6 | 0.015 |
Birthweight (g) | 589 (100%) | 3458 ± 531 | 3221 ± 513 | < 0.001 |
Length (cm) # | 586 (99.4%) | 50.6 ± 2.7 | 49.3 ± 2.5 | < 0.001 |
Head circumference (cm) †† | 587 (99.7%) | 34.6 ± 1.6 | 34.2 ± 1.5 | 0.025 |
Sex—Male | 303 (51.4%) | 266 (87.8%) | 37 (12.2%) | 0.056 |
OGTT Sample | OGTT by FLOXICE Protocol | OGTT by Standard Procedures | Standard OGTT Adjusted by FLOXICE Algorithm | |||
---|---|---|---|---|---|---|
PG | Delay to Analysis (h) | PG | PG Difference v FLOXICE Protocol | PG | PG Difference v FLOXICE Protocol | |
Fasting | 4.9 ± 0.47 | 3.0 ± 0.4 | 4.5 ± 0.51 *** | −0.42 [−0.47 to −0.37] (−9.9% to −7.5%) | 4.9 ± 0.50 | 0.02 [−0.04 to 0.07] (−0.7% to 1.4%) |
1-h | 6.5 ± 1.76 | 2.0 ± 0.4 | 6.1 ± 1.67 *** | −0.38 [−0.47 to −0.28] (−6.8% to −4.8%) | 6.5 ± 1.64 | −0.01 [−0.12 to 0.10] (−1.1% to 1.8%) |
2-h | 5.8 ± 1.25 | 1.1 ± 0.4 | 5.6 ± 1.12 ** | −0.26 [−0.42 to −0.10] (−7.0% to −1.5%) | 5.8 ± 1.07 | −0.02 [−0.18 to 0.13] (−2.9% to 3.2%) |
OGTT Sample | OGTT by FC Mix Protocol | OGTT by Standard Procedures | Standard OGTT Adjusted by FC Mix Algorithm | |||
---|---|---|---|---|---|---|
PG | Delay to Analysis (h) | PG | PG Difference v FC Mix Protocol | PG | PG Difference vs. FC Mix Protocol | |
Fasting | 5.1 ± 0.47 | 3.0 ± 0.4 | 4.5 ± 0.51*** | −0.62 [−0.67 to −0.56] (−13.6% to −10.9%) | 5.1 ± 0.50 | −0.01 [−0.06 to 0.05] (−1.3% to 1.0%) |
1-h | 6.8 ± 1.88 | 2.0 ± 0.4 | 6.1 ± 1.67*** | −0.63 [−0.84 to −0.43] (−11.3% to −7.1%) | 6.8 ± 1.74 | −0.01 [−0.21 to 0.18] (−2.2% to 2.8%) |
2-h | 6.0 ± 1.28 | 1.1 ± 0.4 | 5.6 ± 1.12** | −0.49 [−0.73 to −0.26] (−10.8% to 4.2%) | 6.0 ± 1.28 | −0.03 [−0.20 to 0.14] (−3.1% to 3.5%) |
Mean Glucose ± SD (mmol/L) | n (%) Above Diagnostic Threshold at Each OGTT Sample | Cumulative n (%) Diagnosed with GDM | |||||||
---|---|---|---|---|---|---|---|---|---|
Aboriginal (n = 169) | Other Ethnicity (n = 332) | p-Value | Aboriginal (n = 169) | Other Ethnicity (n = 332) | p-Value | Aboriginal (n = 169) | Other Ethnicity (n = 332) | p-Value | |
Unadjusted OGTT | |||||||||
Fasting PG | 4.2 ± 0.49 | 4.3 ± 0.40 | 0.005 | 9 (5.3%) | 13 (3.9%) | 0.467 | 9 (5.3%) | 13 (3.9%) | 0.467 |
1-h PG | 7.1 ± 1.74 | 6.9 ± 1.72 | 0.208 | 10 (5.9%) | 18 (5.4%) | 0.819 | 14 (8.3%) | 26 (7.8%) | 0.860 |
2-h PG | 6.1 ± 1.63 | 5.9 ± 1.39 | 0.245 | 13 (7.7%) | 18 (5.4%) | 0.319 | 20 (11.8%) | 34 (10.2%) | 0.587 |
FLOXICE adjusted OGTT † | |||||||||
Fasting PG | 4.7 ± 0.47 | 4.8 ± 0.41 | 0.022 | 30 (17.8%) | 86 (25.9%) | 0.041 | 30 (17.8%) | 86 (25.9%) | 0.041 |
1-h PG | 7.6 ± 1.67 | 7.4 ± 1.69 | 0.114 | 14 (8.3%) | 23 (6.9%) | 0.583 | 33 (19.5%) | 96 (28.9%) | 0.023 |
2-h PG | 6.4 ± 1.52 | 6.2 ± 1.32 | 0.126 | 16 (9.5%) | 25 (7.5%) | 0.454 | 39 (23.1%) | 104 (31.3%) | 0.053 |
FC Mix adjusted OGTT | |||||||||
Fasting PG | 4.9 ± 0.46 | 5.0 ± 0.41 | 0.017 | 49 (29.0%) | 147 (44.3%) | 0.001 | 49 (29.0%) | 147 (44.3%) | 0.001 |
1-h PG | 8.0 ± 1.77 | 7.7 ± 1.80 | 0.110 | 17 (10.1%) | 37 (11.1%) | 0.711 | 54 (32.0%) | 159 (47.9%) | 0.001 |
2-h PG | 6.8 ± 1.76 | 6.5 ± 1.52 | 0.111 | 24 (14.2%) | 32 (9.6%) | 0.125 | 61 (36.1%) | 166 (50.0%) | 0.003 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jamieson, E.L.; Spry, E.P.; Kirke, A.B.; Atkinson, D.N.; Marley, J.V. Real-World Gestational Diabetes Screening: Problems with the Oral Glucose Tolerance Test in Rural and Remote Australia. Int. J. Environ. Res. Public Health 2019, 16, 4488. https://doi.org/10.3390/ijerph16224488
Jamieson EL, Spry EP, Kirke AB, Atkinson DN, Marley JV. Real-World Gestational Diabetes Screening: Problems with the Oral Glucose Tolerance Test in Rural and Remote Australia. International Journal of Environmental Research and Public Health. 2019; 16(22):4488. https://doi.org/10.3390/ijerph16224488
Chicago/Turabian StyleJamieson, Emma L., Erica P. Spry, Andrew B. Kirke, David N. Atkinson, and Julia V. Marley. 2019. "Real-World Gestational Diabetes Screening: Problems with the Oral Glucose Tolerance Test in Rural and Remote Australia" International Journal of Environmental Research and Public Health 16, no. 22: 4488. https://doi.org/10.3390/ijerph16224488